What happened with LFMD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
LifeMD runs an online healthcare platform where patients consult clinicians, receive treatment and arrange prescription fulfillment and follow-up care. Its Weight Management Program provides medically supported weight-loss treatment, while Rex MD addresses men’s health and ShapiroMD treats hair loss. These offerings connect medical consultations with medication and continuing care rather than simply selling one-off appointments.
Patients pay for care programs and products, with subscription-based prescription purchases generating most revenue. Virtual primary care under LifeMD+ also accepts direct patient payments and insurance reimbursement. Affiliated physician-owned medical groups make clinical decisions and collect patient or insurance fees; LifeMD supplies the technology and non-clinical administration, and the groups pay it management fees.
The business depends on patients continuing their subscriptions, LifeMD PC and its clinicians delivering care, and partner pharmacies filling prescriptions. State laws restricting corporate medical practice and fee sharing shape the medical-group arrangements. Most consultations occur through messages rather than live conversations where permitted; some states require live communication, limiting how LifeMD can deliver care.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Hims & Hers competes with LifeMD for consumers paying for online care and prescription treatments for weight loss, sexual health, hair loss and hormone health. Its treatment offerings in those areas show the alternatives available to LifeMD’s patients.
LifeMD relies on Novo Nordisk for branded obesity medicines offered through its paid weight-management care; Novo Nordisk makes and sells the drugs, while LifeMD provides the clinical care. Watch access to the Wegovy pill, which LifeMD began offering in January 2026.
LifeMD depends on Lilly’s branded GLP-1 medicines for part of its paid weight-management offering: Lilly makes the drugs, and LifeMD connects eligible patients to them through manufacturer collaborations and pharmacies that fill prescriptions. Access to those medicines is the part of Lilly’s news most directly relevant to LifeMD’s weight-management patients.
Medifast brings paying business to LifeMD’s virtual-care platform, using it to offer its nutrition-plan clients clinically supported weight management, including GLP-1 medicines. Medifast paid LifeMD $10 million from December 2023 through June 2024 to improve the platform, operations and infrastructure, separate from its subsidiary’s equity investment.
Teladoc Health competes with LifeMD in online primary and mental healthcare, but sells much of its care through business customers rather than directly to consumers. Its Integrated Care business is the closer comparison for LifeMD’s primary care, while BetterHelp sells online counseling and therapy to consumers.
Medifast, Inc. earningsMED
Medifast's report will show demand for its nutrition-plan business, a clue to the client channel it brings to LifeMD's virtual weight-management platform.
Look at how Medifast's nutrition-plan business is doing. Stronger demand would support the customer need behind this channel and the possibility of more clients seeking clinical weight-management care through LifeMD; weaker demand would make that source less reassuring. Medifast's results are not LifeMD's platform usage or revenue, so LifeMD's own report must confirm any effect.
Novo-Nordisk A/S earningsNVO
Novo Nordisk's report can show supply and demand for the Wegovy pill, a branded treatment option offered through LifeMD's weight-management care.
Watch what Novo Nordisk says about supply and use of the Wegovy pill. Rising supply alongside stronger use would support demand for a branded option LifeMD offers; constrained supply could make that option harder to provide to eligible weight-management patients. Novo Nordisk's results do not show how many prescriptions LifeMD itself fulfills, so LifeMD's own report must confirm that.
Hims & Hers Health, Inc. earningsHIMS
Hims & Hers Health's report will show demand for online weight-loss, sexual-health, hair-loss and hormone treatments, where it competes with LifeMD for consumers.
Watch demand and sales in Hims & Hers' online-care and prescription-treatment offerings that overlap with LifeMD's. Strength would show consumers are paying for these services, but also that LifeMD faces active competition for attractive customers. Weakness could point to softer demand for the category; it would not by itself mean customers are moving to LifeMD.
LifeMD, Inc. earningsThis company
LifeMD relies mainly on subscriptions, and this report will show whether patient revenue keeps growing enough to cover the cost of providing care.
Read telehealth revenue alongside the operating loss from continuing operations, and check whether the cost of telehealth services is rising sharply with revenue. Growing revenue, contained service costs and a narrower continuing-operations loss would show subscriptions covering more of the cost of the platform, clinicians and pharmacy fulfillment. Slower revenue or faster-rising costs with a wider loss would show that growth is not yet paying for the service.
